Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Herceptin
Herceptin 150 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-090903 · Präparat HOS-084155
Data from study JP16003, a single-arm study of Herceptin (4 mg/kg IV loading dose and 2 mg/kg IV
weekly) and docetaxel (60 mg/m2 IV) in Japanese women with HER2- positive MBC, suggested that
concomitant administration of Herceptin had no effect on the single dose pharmacokinetics of
docetaxel. Study JP19959 was a substudy of BO18255 (ToGA) performed in male and female
Japanese patients with advanced gastric cancer to study the pharmacokinetics of capecitabine and
cisplatin when used with or without Herceptin. The results of this substudy suggested that the
exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine was not affected by concurrent use of
cisplatin or by concurrent use of cisplatin plus Herceptin. However, capecitabine itself showed higher
concentrations and a longer half-life when combined with Herceptin. The data also suggested that the
pharmacokinetics of cisplatin were not affected by concurrent use of capecitabine or by concurrent use
of capecitabine plus Herceptin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): docetaxel (HOS-084505) capecitabine (HOS-090904) cisplatin (HOS-086022)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-25T17:43:00Z · SHA-256 4737cd7c26cd2805fc40be61983542b3a3127abbce7e3ca6ebc3b5c0895dda53 · Passage a93c204c81ec5f58911cd3af5f32bc3a7049d0beec0577a8026374dcf36e5639 · Zeichen 864–1869 im Abschnitt
Wechselwirkungen · Herceptin
Herceptin 600 mg solution for injection in vial · Abschnitt 4.5 · PDF-Seite 40
HOS-090952 · Präparat HOS-084155
Data from study JP16003, a single-arm study of Herceptin (4 mg/kg IV loading dose and 2 mg/kg IV
weekly) and docetaxel (60 mg/m2 IV) in Japanese women with HER2- positive MBC, suggested that
concomitant administration of Herceptin had no effect on the single dose pharmacokinetics of
docetaxel. Study JP19959 was a substudy of BO18255 (ToGA) performed in male and female
Japanese patients with advanced gastric cancer to study the pharmacokinetics of capecitabine and
cisplatin when used with or without Herceptin. The results of this substudy suggested that the
exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine was not affected by concurrent use of
cisplatin or by concurrent use of cisplatin plus Herceptin. However, capecitabine itself showed higher
concentrations and a longer half-life when combined with Herceptin. The data also suggested that the
pharmacokinetics of cisplatin were not affected by concurrent use of capecitabine or by concurrent use
of capecitabine plus Herceptin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): docetaxel (HOS-084505) capecitabine (HOS-090904) cisplatin (HOS-086022)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-25T17:43:00Z · SHA-256 4737cd7c26cd2805fc40be61983542b3a3127abbce7e3ca6ebc3b5c0895dda53 · Passage a93c204c81ec5f58911cd3af5f32bc3a7049d0beec0577a8026374dcf36e5639 · Zeichen 864–1869 im Abschnitt
Wechselwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-138162 · Präparat HOS-098156
Data from study JP16003, a single-arm study of trastuzumab (4 mg/kg intravenous loading dose and
2 mg/kg intravenous weekly) and docetaxel (60 mg/m2 intravenous) in Japanese women with
HER2 positive MBC, suggested that concomitant administration of trastuzumab had no effect on the
single-dose pharmacokinetics of docetaxel. Study JP19959 was a substudy of BO18255 (ToGA)
performed in male and female Japanese patients with advanced gastric cancer to study the
pharmacokinetics of capecitabine and cisplatin when used with or without trastuzumab. The results of
this substudy suggested that the exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine was
not affected by concurrent use of cisplatin or by concurrent use of cisplatin plus trastuzumab.
However, capecitabine itself showed higher concentrations and a longer half-life when combined with
trastuzumab. The data also suggested that the pharmacokinetics of cisplatin were not affected by
concurrent use of capecitabine or by concurrent use of capecitabine plus trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): docetaxel (HOS-084505) capecitabine (HOS-090904) cisplatin (HOS-086022)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage 7a062850acffd18c6e3ed8a2f09c22becae79551f36c25729ddfc1cf8bf4fb44 · Zeichen 883–1926 im Abschnitt
Wechselwirkungen · Trazimera
Trazimera 150 mg powder for concentrate for solution for infusion Trazimera 420 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-139505 · Präparat HOS-098360
Data from study JP16003, a single-arm study of trastuzumab (4 mg/kg intravenous loading dose and
2 mg/kg intravenous dose weekly) and docetaxel (60 mg/m2 intravenous dose) in Japanese women
with HER2-positive MBC, suggested that concomitant administration of trastuzumab had no effect
on the single-dose pharmacokinetics of docetaxel. Study JP19959 was a substudy of BO18255
(ToGA) performed in male and female Japanese patients with advanced gastric cancer to study the
pharmacokinetics of capecitabine and cisplatin when used with or without trastuzumab. The results
of this substudy suggested that the exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine
was not affected by concurrent use of cisplatin or by concurrent use of cisplatin plus trastuzumab.
However, capecitabine itself showed higher concentrations and a longer half-life when combined
with trastuzumab. The data also suggested that the pharmacokinetics of cisplatin were not affected
by concurrent use of capecitabine or by concurrent use of capecitabine plus trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): docetaxel (HOS-084505) capecitabine (HOS-090904) cisplatin (HOS-086022)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-08T10:10:00Z · SHA-256 9fdaf2b6f4270ea70563d54731dd8a8b47224a5c6f4970a6433712c7e0145f3f · Passage 881b99ae7fc758cda05218d0b796dfdca115d92ed06199cdfd460a7c7d50db09 · Zeichen 888–1941 im Abschnitt
Wechselwirkungen · Phesgo
Phesgo 600 mg/600 mg solution for injection Phesgo 1 200 mg/600 mg solution for injection · Abschnitt 4.5 · PDF-Seite 8
HOS-146985 · Präparat HOS-099594
Five studies evaluated the effects of pertuzumab on the PK of co-administered cytotoxic agents,
docetaxel, paclitaxel, gemcitabine, capecitabine, carboplatin and erlotinib. There was no evidence of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): docetaxel (HOS-084505) paclitaxel (HOS-087959) gemcitabine (HOS-113530) capecitabine (HOS-090904) carboplatin (HOS-084540) erlotinib (HOS-113527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-28T11:50:00Z · SHA-256 a6c98bf6b55eca9607a319c3be5d77798ac324754cdfd92882fd80d342fc312e · Passage f2a0cd1011807caefd2618c0dce843032115e8784a0fc65811243137e81e71b1 · Zeichen 551–748 im Abschnitt
Wechselwirkungen · Phesgo
Phesgo 600 mg/600 mg solution for injection Phesgo 1 200 mg/600 mg solution for injection · Abschnitt 4.5 · PDF-Seite 9
HOS-146995 · Präparat HOS-099594
Data from study JP16003, a single-arm study of trastuzumab (4 mg/kg intravenous loading dose and
2 mg/kg intravenous weekly) and docetaxel (60 mg/m2 intravenous) in Japanese women with
HER2-positive metastatic breast cancer, suggested that concomitant administration of trastuzumab had
no effect on the single dose pharmacokinetics of docetaxel. Study JP19959 was a substudy of
BO18255 (ToGA) performed in male and female Japanese patients with advanced gastric cancer to
study the pharmacokinetics of capecitabine and cisplatin when used with or without trastuzumab. The
results of this substudy suggested that the exposure to the bioactive metabolites (e.g. 5-FU) of
capecitabine was not affected by concurrent use of cisplatin or by concurrent use of cisplatin plus
trastuzumab. However, capecitabine itself showed higher concentrations and a longer half-life when
combined with trastuzumab. The data also suggested that the pharmacokinetics of cisplatin were not
affected by concurrent use of capecitabine or by concurrent use of capecitabine plus trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): docetaxel (HOS-084505) capecitabine (HOS-090904) cisplatin (HOS-086022)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-28T11:50:00Z · SHA-256 a6c98bf6b55eca9607a319c3be5d77798ac324754cdfd92882fd80d342fc312e · Passage 1dc560e67a455e29b404ce69db758523ac92f20f882d155d3728a839f9855c8f · Zeichen 1868–2932 im Abschnitt
Wechselwirkungen · Herwenda
Herwenda 150 mg powder for concentrate for solution for infusion Herwenda 420 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-149368 · Präparat HOS-100044
Data from study JP16003, a single-arm study of trastuzumab (4 mg/kg intravenous loading dose and
2 mg/kg intravenous weekly) and docetaxel (60 mg/m2 intravenous) in Japanese women with HER2
positive MBC, suggested that concomitant administration of trastuzumab had no effect on the single
dose pharmacokinetics of docetaxel. Study JP19959 was a substudy of BO18255 (ToGA) performed
in male and female Japanese patients with advanced gastric cancer to study the pharmacokinetics of
capecitabine and cisplatin when used with or without trastuzumab. The results of this substudy
suggested that the exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine was not affected
by concurrent use of cisplatin or by concurrent use of cisplatin plus trastuzumab. However,
capecitabine itself showed higher concentrations and a longer half-life when combined with
trastuzumab. The data also suggested that the pharmacokinetics of cisplatin were not affected by
concurrent use of capecitabine or by concurrent use of capecitabine plus trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): docetaxel (HOS-084505) capecitabine (HOS-090904) cisplatin (HOS-086022)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T17:30:00Z · SHA-256 0420b6f06ca3e337d4516096fe98f47fc8d3f966fddcad79ddc2566b63477530 · Passage 094f48665d2293ae29c3f2f58ae4f28f7cbe5f1008d7589c49b71b15304e6a3f · Zeichen 886–1929 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.